These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 38134439)

  • 1. Probing the Dissociation Pathway of a Kinetically Labile Transthyretin Mutant.
    Sun X; Ferguson JA; Leach BI; Stanfield RL; Dyson HJ; Wright PE
    J Am Chem Soc; 2024 Jan; 146(1):532-542. PubMed ID: 38134439
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mispacking of the F87 sidechain drives aggregation-promoting conformational fluctuations in the subunit interfaces of the transthyretin tetramer.
    Sun X; Ferguson JA; Yang K; Stanfield RL; Dyson HJ; Wright PE
    Protein Sci; 2024 Sep; 33(9):e5101. PubMed ID: 39149996
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mispacking of the Phe87 Side Chain Reduces the Kinetic Stability of Human Transthyretin.
    Sun X; Jaeger M; Kelly JW; Dyson HJ; Wright PE
    Biochemistry; 2018 Dec; 57(51):6919-6922. PubMed ID: 30540442
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dissecting the structure, thermodynamic stability, and aggregation properties of the A25T transthyretin (A25T-TTR) variant involved in leptomeningeal amyloidosis: identifying protein partners that co-aggregate during A25T-TTR fibrillogenesis in cerebrospinal fluid.
    Azevedo EP; Pereira HM; Garratt RC; Kelly JW; Foguel D; Palhano FL
    Biochemistry; 2011 Dec; 50(51):11070-83. PubMed ID: 22091638
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Kinetic analysis of the multistep aggregation pathway of human transthyretin.
    Sun X; Dyson HJ; Wright PE
    Proc Natl Acad Sci U S A; 2018 Jul; 115(27):E6201-E6208. PubMed ID: 29915031
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Energetic characteristics of the new transthyretin variant A25T may explain its atypical central nervous system pathology.
    Sekijima Y; Hammarström P; Matsumura M; Shimizu Y; Iwata M; Tokuda T; Ikeda S; Kelly JW
    Lab Invest; 2003 Mar; 83(3):409-17. PubMed ID: 12649341
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Conformational Dynamics of an Amyloidogenic Intermediate of Transthyretin: Implications for Structural Remodeling and Amyloid Formation.
    Leach BI; Ferguson JA; Morgan G; Sun X; Kroon G; Oyen D; Dyson HJ; Wright PE
    J Mol Biol; 2024 Aug; 436(16):168673. PubMed ID: 38909653
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A transthyretin monomer intermediate undergoes local unfolding and transient interaction with oligomers in a kinetically concerted aggregation pathway.
    Sun X; Ferguson JA; Dyson HJ; Wright PE
    J Biol Chem; 2022 Aug; 298(8):102162. PubMed ID: 35724960
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thermodynamic Stability and Aggregation Kinetics of EF Helix and EF Loop Variants of Transthyretin.
    Ferguson JA; Sun X; Dyson HJ; Wright PE
    Biochemistry; 2021 Mar; 60(10):756-764. PubMed ID: 33645214
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mispacking of the F87 sidechain drives aggregation-promoting conformational fluctuations in the subunit interfaces of the transthyretin tetramer.
    Sun X; Ferguson JA; Yang K; Stanfield RL; Dyson HJ; Wright PE
    bioRxiv; 2024 Mar; ():. PubMed ID: 38464206
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quantification of the thermodynamically linked quaternary and tertiary structural stabilities of transthyretin and its disease-associated variants: the relationship between stability and amyloidosis.
    Hurshman Babbes AR; Powers ET; Kelly JW
    Biochemistry; 2008 Jul; 47(26):6969-84. PubMed ID: 18537267
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Disease-associated mutations impacting BC-loop flexibility trigger long-range transthyretin tetramer destabilization and aggregation.
    Esperante SA; Varejāo N; Pinheiro F; Sant'Anna R; Luque-Ortega JR; Alfonso C; Sora V; Papaleo E; Rivas G; Reverter D; Ventura S
    J Biol Chem; 2021 Sep; 297(3):101039. PubMed ID: 34343569
    [TBL] [Abstract][Full Text] [Related]  

  • 13. NMR Measurements Reveal the Structural Basis of Transthyretin Destabilization by Pathogenic Mutations.
    Leach BI; Zhang X; Kelly JW; Dyson HJ; Wright PE
    Biochemistry; 2018 Jul; 57(30):4421-4430. PubMed ID: 29972637
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluating the effect of mutations and ligand binding on transthyretin homotetramer dynamics.
    Saldaño TE; Zanotti G; Parisi G; Fernandez-Alberti S
    PLoS One; 2017; 12(7):e0181019. PubMed ID: 28704493
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Retention of misfolded mutant transthyretin by the chaperone BiP/GRP78 mitigates amyloidogenesis.
    Sörgjerd K; Ghafouri B; Jonsson BH; Kelly JW; Blond SY; Hammarström P
    J Mol Biol; 2006 Feb; 356(2):469-82. PubMed ID: 16376939
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mutation and low pH effect on the stability as well as unfolding kinetics of transthyretin dimer.
    Xue Q; Zheng QC; Zhang JL; Cui YL; Chu WT; Zhang HX
    Biophys Chem; 2014 May; 189():8-15. PubMed ID: 24632442
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of the transthyretin acid denaturation pathways by analytical ultracentrifugation: implications for wild-type, V30M, and L55P amyloid fibril formation.
    Lashuel HA; Lai Z; Kelly JW
    Biochemistry; 1998 Dec; 37(51):17851-64. PubMed ID: 9922152
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The pathway by which the tetrameric protein transthyretin dissociates.
    Foss TR; Wiseman RL; Kelly JW
    Biochemistry; 2005 Nov; 44(47):15525-33. PubMed ID: 16300401
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tolcapone, a potent aggregation inhibitor for the treatment of familial leptomeningeal amyloidosis.
    Pinheiro F; Varejão N; Esperante S; Santos J; Velázquez-Campoy A; Reverter D; Pallarès I; Ventura S
    FEBS J; 2021 Jan; 288(1):310-324. PubMed ID: 32324953
    [TBL] [Abstract][Full Text] [Related]  

  • 20. D18G transthyretin is monomeric, aggregation prone, and not detectable in plasma and cerebrospinal fluid: a prescription for central nervous system amyloidosis?
    Hammarström P; Sekijima Y; White JT; Wiseman RL; Lim A; Costello CE; Altland K; Garzuly F; Budka H; Kelly JW
    Biochemistry; 2003 Jun; 42(22):6656-63. PubMed ID: 12779320
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.